Abstract:Resveratrol, a naturally occurring stilbene, exhibits numerous beneficial health effects. Various studies have demonstrated its diverse biological actions, including anti-oxidant, anti-inflammatory, and anti-platelet properties, thereby supporting its potential for cardio protection, neuroprotection, and anti-cancer activity. However, a significant limitation of resveratrol is its weak bioavailability. To overcome this challenge, multiple research groups have investigated the synthesis of new resveratrol derivatives to enhance bioavailability and pharmacological activities. Nevertheless, there are limited data on the effects of resveratrol derivatives on platelet function. Therefore, the objective of this study was to synthesize resveratrol methoxy derivatives and evaluate their anti-platelet and anti-proliferative activity. Platelet-rich plasma (PRP) obtained from healthy volunteers was utilized to assess the derivatives' ability to inhibit platelet aggregation induced by platelet activating factor (PAF), adenosine diphosphate (ADP), and thrombin receptor activating peptide (TRAP). Additionally, the derivatives' anti-tumor activity was evaluated against the proliferation of PC-3 and HCT116 cells. The results revealed that some methoxy derivatives of resveratrol exhibited comparable or even superior anti-platelet activity compared to the original compound. The most potent derivative was the 4′-methoxy derivative, which demonstrated approximately 2.5 orders of magnitude higher anti-platelet activity against TRAP-induced platelet aggregation, indicating its potential as an anti-platelet agent. Concerning in silico studies, the 4′-methyl group of 4′-methoxy derivative is oriented similarly to the fluorophenyl–pyridyl group of Vorapaxar, buried in a hydrophobic cavity. In terms of their anti-tumor activity, 3-MRESV exhibited the highest potency in PC-3 cells, while 3,4′-DMRESV and TMRESV showed the greatest efficacy in HCT116 cells. In conclusion, methoxy derivatives of resveratrol possess similar or improved anti-platelet and anti-cancer effects, thereby holding potential as bioactive compounds in various pathological conditions.

Resveratrol derivatives: an updated patent review (2012-2015)

Resveratrol derivatives: a patent review (2009 – 2012)

Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease.

Resveratrol Derivatives As Promising Chemopreventive Agents with Improved Potency and Selectivity.

Recent Advances in Synthesis, Bioactivity, and Pharmacokinetics of Pterostilbene, an Important Analog of Resveratrol

Structure Modification of Resveratrol and Pharmacological Activity

Pharmacological Activities and Structure-Modification of Resveratrol Analogues.

Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It?

Resveratrol:A review of plant sources, synthesis, stability, modification and food application.

Design and synthesis of resveratrol analogs

Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound

Biotechnological Advances in Resveratrol Production and its Chemical Diversity

Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016)

Recent advances in nanodelivery systems of resveratrol and their biomedical and food applications: a review

Obtaining Resveratrol: from Chemical Synthesis to Biotechnological Production

Synthesis and Biological Evaluation of Resveratrol Methoxy Derivatives

Recent progress in nanotechnology-based drug carriers for resveratrol delivery

Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)

Resveratrol: A Double-Edged Sword in Health Benefits

Caffeic acid derivatives, analogs and applications: a patent review (2009 – 2013)

Therapeutic potential of resveratrol: the in vivo evidence